..
Biogen Idec, Inc. (Massachusetts)
14 Cambridge Center
Cambridge
Massachusetts
02142
U.S.A.
Phone:
617-679-2000
Fax:
617-679-2617
|
Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.
Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.
With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.
For product labeling, press releases and additional information about the company, please visit www.biogenidec.com
Email:
Ownership:
Public
Web Site:
Biogen Idec, Inc. (Massachusetts)
Employees:
1700
Symbol: BIIB
|
|
|
Company News |
Genentech (RHHBY) and Biogen Idec, Inc. (Massachusetts) (BIIB) Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
5/17/2013 9:13:20 AM
More...
|
FDA Accepts Biogen Idec, Inc. (Massachusetts) (BIIB)’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A
5/13/2013 11:06:30 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) to Report First Quarter 2013 Financial Results on April 25, 2013
4/11/2013 6:49:10 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Exec Explains $55,000 Annual Cost of New Drug
4/5/2013 8:50:08 AM
More...
|
The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Biogen Idec, Inc. (Massachusetts) (BIIB) Daclizumab HYP in Multiple Sclerosis
4/4/2013 11:49:44 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Completes Purchase of Full Rights and Control of TYSABRI®
4/3/2013 11:01:50 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Prices New MS Pill Below Rival Meds
4/1/2013 7:08:00 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Wins FDA Approval for Blockbuster Oral MS Drug
3/28/2013 7:23:54 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Multiple Sclerosis Drug Wins EU Agency's Backing
3/22/2013 7:24:12 AM
More...
|
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: U.S. Patent Office Grants Patent Claiming Dosing Regimen for TECFIDERA™ (Dimethyl Fumarate)
3/20/2013 10:05:09 AM
More...
|
|
|
|